Newsfeeds - Spark Newswire

1 minute read

Morgan Stanley Downgrades Cyteir Therapeutics to Underweight, Lowers Price Target to $2

Today, 8:45 PM

Morgan Stanley analyst Jeffrey Hung downgrades Cyteir Therapeutics (NASDAQ:CYT) from Equal-Weight to Underweight and lowers the price target from $4 to $2.

CYT

1 minute read

B of A Securities Downgrades Cyteir Therapeutics to Neutral, Lowers Price Target to $2

By Benzinga Newsdesk

Today, 8:45 PM

B of A Securities analyst Tazeen Ahmad downgrades Cyteir Therapeutics (NASDAQ:CYT) from Buy to Neutral and lowers the price target from $4 to $2.

CYT

1 minute read

JP Morgan Downgrades Cyteir Therapeutics to Neutral

By Benzinga Newsdesk

Today, 8:45 PM

JP Morgan analyst Anupam Rama downgrades Cyteir Therapeutics (NASDAQ:CYT) from Overweight to Neutral.

CYT

13 minute read

Options

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

Today, 8:45 PM

Wednesday saw 219 companies set new 52-week lows.

$APE

2 minute read

News

5 Value Stocks In The Healthcare Sector

By Benzinga Insights

Today, 8:45 PM

What are Value Stocks?

CYT

12 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For September 9, 2022

By Benzinga Insights

Today, 8:45 PM

Upgrades

ADCT

1 minute read

Cyteir Therapeutics Q2 EPS $(0.34) Up From $(4.83) YoY

By Benzinga Newsdesk

Today, 8:45 PM

Cyteir Therapeutics (NASDAQ:CYT) reported quarterly losses of $(0.34) per share. This is a 92.96 percent increase over losses of $(4.83) per share from the same period last year.

CYT

5 minute read

Why This Biotechnology Surged More Than 60%; Here Are 67 Biggest Movers From Yesterday

By Lisa Levin

Today, 8:45 PM

Gainers Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) shares surged 94.3% to close at $1.69 on Tuesday after the company filed a request for the withdrawal of the Registration Statement on Form S-1.

AAMC

5 minute read

79 Biggest Movers From Yesterday

By Lisa Levin

Today, 8:45 PM

Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 154.7% to settle at $12.10 on Tuesday on continued strength after the FDA granted clearance for the company's pūrgo technology, classifying it as a class II medical device.

ADTH

4 minute read

Cyteir Therapeutics Announced CYT-0851 Phase 1 Dose Escalation Results Show Early Clinical Activity and Generally Well Tolerated Safety Profile in Advanced Solid Tumors and Hematologic Malignancies in Data Presented at ASCO

By Charles Gross

Today, 8:45 PM

Cyteir Therapeutics, Inc.

CYT